Araki, Eiichi

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 3,079

Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein

Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, D. A., Goldstein, B. J., & White, M. F. (1991) · Nature

Metabolism, Diabetes, and CancerProtein Kinase Regulation and GTPase Signaling

Cited by 1,574

Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene

Araki, E., Lipes, M. A., Patti, M.-E., Brüning, J. C., Haag III, B., Johnson, R. S., & Kahn, C. R. (1994) · Nature

Metabolism, Diabetes, and CancerGrowth Hormone and Insulin-like Growth Factors

Cited by 1,252

Adiponectin Stimulates AMP-Activated Protein Kinase in the Hypothalamus and Increases Food Intake

Kubota, N., Yano, W., Kubota, T., Yamauchi, T., Itoh, S., Kumagai, H., Kozono, H., Takamoto, I., Okamoto, S., Shiuchi, T., et al. (2007) · Cell Metabolism

Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases

Cited by 844

Targeted disruption of the chop gene delays endoplasmic reticulum stress-mediated diabetes

Oyadomari, S., Koizumi, A., Takeda, K., Gotoh, T., Akira, S., Araki, E., & Mori, M. (2002) · Journal of Clinical Investigation

Endoplasmic Reticulum Stress and DiseasePancreatic function and diabetes

Cited by 752

Report of the Committee on the classification and diagnostic criteria of diabetes mellitus: The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus

Seino, Y., Nanjo, K., Tajima, N., Kadowaki, T., Kashiwagi, A., Araki, E., Ito, C., Inagaki, N., Iwamoto, Y., Kasuga, M., et al. (2010) · Diabetology International

Diabetes Management and ResearchDiabetes and associated disorders

Cited by 614

Japanese clinical practice guideline for diabetes 2019

Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International

Diabetes Treatment and ManagementClinical practice guidelines implementation

Cited by 545

Activation of AMP-Activated Protein Kinase Reduces Hyperglycemia-Induced Mitochondrial Reactive Oxygen Species Production and Promotes Mitochondrial Biogenesis in Human Umbilical Vein Endothelial Cells

Kukidome, D., Nishikawa, T., Sonoda, K., Imoto, K., Fujisawa, K., Yano, M., Motoshima, H., Taguchi, T., Matsumura, T., & Araki, E. (2006) · Diabetes

Metabolism, Diabetes, and CancerMitochondrial Function and Pathology

Cited by 504

Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.

Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 412

Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications.

Nishikawa, T., & Araki, E. (2007) · Antioxidants & Redox Signaling

Mitochondrial Function and PathologyNitric Oxide and Endothelin Effects

Cited by 391

Reactive Oxygen Species from Mitochondria Induce Cyclooxygenase-2 Gene Expression in Human Mesangial Cells

Kiritoshi, S., Nishikawa, T., Sonoda, K., Kukidome, D., Senokuchi, T., Matsuo, T., Matsumura, T., Tokunaga, H., Brownlee, M., & Araki, E. (2003) · Diabetes

Inflammatory mediators and NSAID effectsChronic Kidney Disease and Diabetes

Cited by 345

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, A., Ohashi, K., Hara, K., et al. (2017) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 313

Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.

Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 300

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Mathieu, C., Dandona, P., Gillard, P., Senior, P., Hasslacher, C., Araki, E., Lind, M., Bain, S. C., Jabbour, S., Arya, N., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 252

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 208

Evaluation of Urinary 8-Hydroxydeoxy-Guanosine as a Novel Biomarker of Macrovascular Complications in Type 2 Diabetes

Nishikawa, T., Sasahara, T., Kiritoshi, S., Sonoda, K., Senokuchi, T., Matsuo, T., Kukidome, D., Wake, N., Matsumura, T., Miyamura, N., et al. (2003) · Diabetes Care

Advanced Glycation End Products researchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 190

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Ishibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 184

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 164

Endoplasmic Reticulum Stress and Diabetes Mellitus.

ARAKI, E., OYADOMARI, S., & MORI, M. (2003) · Internal Medicine

Endoplasmic Reticulum Stress and DiseasePancreatic function and diabetes

Cited by 151

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 136

Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia

Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis

Lipoproteins and Cardiovascular HealthPeroxisome Proliferator-Activated Receptors

Cited by 124

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 79

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate

Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Yokote, K., Arai, H., Araki, E., & Ishibashi, S. (2021) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 14

A Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Indicated Significant Improvement in Glycemic and Liver Function-related Parameters

Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2018) · Atherosclerosis Supplements

Lipoproteins and Cardiovascular HealthMicroRNA in disease regulation

Cited by 11